Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

At the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, Novavax CEO John Jacobs outlined the company's evolution from a vertically integrated commercial entity focused on its COVID-19 vaccine, Nuvaxovid, to a business model emphasizing R&D and diversified partnerships, a shift initiated in early 2023.

Analysis

Novavax, Inc. (NVAX), at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, detailed a significant evolution in its business model, as articulated by CEO John Jacobs. The company has pivoted from its 2020-2022 strategy as a vertically integrated commercial organization, where the vast majority of its resources were dedicated to the launch and global introduction of its COVID-19 vaccine, Nuvaxovid. Since early 2023, Novavax has been reorienting towards a model that emphasizes research and development (R&D) and diversified partnerships. This strategic shift indicates a deliberate move away from the capital-intensive and resource-heavy approach of direct commercialization for a singular product, towards leveraging its R&D capabilities and platform technology through collaborations. Associated sentiment signals suggest this transition is viewed with mild optimism, although the CEO's standard cautionary note regarding forward-looking statements reminds investors of the inherent execution risks.

Key Decisions for Investors

• Investors should closely monitor Novavax's execution of its R&D and partnership-focused strategy, looking for tangible progress in pipeline development and the successful establishment of new, value-accretive collaborations.
• Evaluate the financial implications of this strategic shift, particularly changes in operating expenses, R&D investment levels, and future revenue projections stemming from partnerships as opposed to direct Nuvaxovid sales.
• Consider how this refined business model alters Novavax's risk profile and long-term growth prospects, especially regarding its ability to diversify beyond its initial COVID-19 vaccine and generate sustainable value through its R&D engine.